Latest Health News

Sarama Resources Ltd reported a $1.9 million loss for the first nine months of 2025 while securing A$2.7 million in equity funding and advancing a $242 million arbitration claim against Burkina Faso over mining permit expropriation.

Predictive Discovery Limited’s definitive feasibility study for the Bankan Gold Project in Guinea reveals a substantial 2.95 million ounce gold reserve and strong project economics, supported by comprehensive environmental and social approvals.

AXP Energy reports encouraging early oil and gas flowback at its Charlie #1 well in Oklahoma, marking a key milestone in its Mississippi Lime development program.

DPM Metals has announced a fourth quarter dividend of US$0.04 per share, payable in January 2026, with shareholders given the option to receive payments in US or Canadian dollars.

DPM Metals delivered record third quarter financial results driven by strong free cash flow and adjusted net earnings, while its recent acquisition of Adriatic Metals' Vareš operation promises higher-than-expected production in 2026.

Lendlease has reported a return to profit in FY25 alongside significant capital recycling and board renewal, setting the stage for a strategic transition year in FY26 with a planned $500 million share buyback.

Senetas Corporation has streamlined its operations following the sale of Votiro, reporting a strong financial position and unveiling plans for a significant capital return and share consolidation.

Biotron Limited’s lead HBV drug BIT-HBV001 demonstrates superior antiviral activity and synergy with the current standard treatment Tenofovir in preclinical models, advancing hopes for a more effective Hepatitis B therapy.

Bio-Gene Technology’s natural insecticide Qcide® has earned organic listing status from the US Organic Materials Review Institute, marking a pivotal step for its entry into the organic pest control market.

The Foreign Investment Review Board has extended its deadline for approving Mayne Pharma's acquisition by Cosette Pharmaceuticals, maintaining the current transaction timetable for now.

Island Pharmaceuticals will host a webinar to discuss the FDA's feedback on the clinical development and regulatory approval of its antiviral drug Galidesivir, including key considerations under the FDA's Animal Rule and Priority Review Voucher eligibility.

Resonance Health has revealed ambitious growth plans at its 2025 AGM, projecting revenue to nearly quadruple by FY26 while maintaining positive EBITDA guidance. The company is broadening its global footprint and diversifying its clinical trial services across multiple therapeutic areas.